disease in adults may usually be detected by standard malabsorption tests such as measuring blood folate, r-xylose absorption, and fat absorption (1). These tests are not necessarily applicable to children, however, the last test in particular requiring good patient compliance and preferably carried out in hospital during several days to ensure complete sampling. Furthermore, in children the clinical sensitivity of standard malabsorption tests appears to be lower than in adults (2, 3). For this reason smallintestinal biopsy has been recommended as a primary investigation in suspected celiac disease in children. Alternative procedures are wanted to select patients for smallintestinal biopsy that, when performed before and after dietary gluten withdrawal as well as during gluten challenge, may provide a definite diagnosis of celiac disease according to the present standards (4).
Besterman et al. reported in 1978(5) that the enteroglu-
cagon concentrations in plasma were significantly greater in untreated celiac disease in adults than in control subjects and subjects treated for celiac disease. Enteroglucagon, an intestinal peptide with a maximal mucosal content in the distal small intestine, is released into the circulation after a meal or an oral glucose load (6). Its physiological role in humans is unknown, but a trophic effect on the intestinal mucosa has been suggested (7); animal experiments also indicate an inhibitory effect on the gastric acid secretion (8). In celiac disease the proximal part of the small intestine is more severely affected than the distal part (9, 10), and the increased concentration of enteroglucagon in celiac disease is possibly a result of an increased release of this peptide from the distal part of the small intestine and the colon when unabsorbed intestinal contents reach these lower parts of the intestine (5).
In the present study we wanted to evaluate the usefulness of the assay for plasma enteroglucagon in distinguishing which children should undergo small-intestinal biopsy when celiac disease is suspected.
Materials and Methods

Subjects
The patients were studied during the period 1979-1982 at the Pediatric Clinic in the Central Hospital in Norrkoping, Sweden. All children within the area of Norrkoping who require in-hospital investigation, e.g., small-intestinal biopsies, are referred to this clinic in accordance with healthservice regulations. This study includes all 74 children with suspected celiac disease from whom small-intestinal biopsies and blood samples for analysis of enteroglucagon were obtained. Celiac disease. Fourteen children, seven girls and seven boys, ages seven months to 7.5 years (mean 1.6years) were studied before gluten withdrawal.
All had subtotal villous atrophy of the small-intestinal mucosa and improved clinically on a gluten-free diet. The diagnosis of celiac disease was established in 10 patients by demonstration of improvement of the small-intestinal mucosal findings on a glutenfree diet and of relapse during gluten challenge (4). The other four patients had no other features to suggest any other cause for their villous atrophy and were therefore classified as "probable" celiac disease, pending the diagnostic results after gluten withdrawal and gluten challenge.
Other gastrointestinal
disease. This group comprised 45 children, 28 girls and 17 boys, ages two months to 16 years (mean 3.1years). In these children small bowel biopsies were performed because celiac disease was suspected. Main symptoms were diarrhea and (or) a low rate of weight gain in 33 patients, and various other symptoms in seven patients (e.g., constipation, anorexia, and protein-losing enteropathy). In these 40 patients the diagnosis of celiac disease was ruled out by normal or only mildly abnormal smallintestinal biopsy findings. Three other patients with later proven intolerance to cow's milk had villous atrophy of the small-intestinal mucosa (one subtotal and two partial). Two patients with transient gluten intolerance were also studied; they had previously had subtotal villous atrophy and had shown improvement after gluten withdrawal. No relapse of the intestinal biopsy findings was demonstrated during gluten challenge. At the time of this study they had been on a normal diet for more than 24 months, and smallintestinal biopsy findings for both were normal.
No gastrointestinal disease.
This group comprised 15 children, six boys and nine girls, ages one to 15years (mean 
Measurement of enteroglucagon in plasma.
Enteroglucagonconcentrations were determined by radioimmunoassay (11) with reagents from Novo Research Institute, Bagsvaerd, Denmark. The performance of the assay in our hands will be described separately in detail (12). In brief, to determine total plasma glucagon immunoreactivity, we used antibody K 4023; for the pancreatic glucagon immunoreactivity we used antibody K 5563. Purified porcine pancreatic glucagon was the calibrator in both assays. The difference between the concentrations measured with these antibodies was taken as the concentration of plasma enteroglucagon (11). Three plasma pools (obtained from plasma sampled as described above) were analyzed at the start of each assay run; two of them were also analyzed at the end of each run. The within-assay bias and imprecision was calculated from the differences in values obtained for the two pools. The between-assay imprecision was calculated from the between-run differences for each pool sample. There was no demonstrable within-assay bias (assay drift). The withinassay coefficient of variation (CV) was about 6%; the total between-assay CV was 10-14%.
Statistical analysis.
Student's t-test was used for analysis of significances.
The regression line was determined by the method of least squares (13). 
Results
Concentrations
Discussion
This study showed higher mean basal and postprandial concentrations of enteroglucagon in children with celiac disease than in two comparison groups of children, which agrees with the single earlier report on adults with untreated celiac disease (5). We have also found that all cases with subtotal villous atrophy (14 children with celiac disease and one child with untreated cow'smilk intolerance) had plasma concentrations of enteroglucagon exceeding the mean + 2 (20) , and antibodies to gliadin occur more frequently in celiac disease than in other gastrointestinal diseases (21) (22) (23) . No comparison between the determination of plasma enteroglucagon and these other tests for diagnosis of celiac disease has to our knowledge been reported. Although none of the methods are specific for celiac disease, they can probably all improve the selection of patients for small-bowel biopsy and might therefore facilitate the follow-up after gluten withdrawal. Further studies of the discriminatory value and general applicability of the different tests are warranted.
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